$3.63 0.00 (%) AEterna Zentaris Inc - NASDAQ

Aug. 30, 2016 | 04:00 PM

Partner Headlines

  1. AEterna Zentraris Surged 17%: Here Is What You Need To Know

    Benzinga | Jan. 25, 2016 | 13:27PM EST
  2. Mid-Morning Market Update: Markets Open Higher; Bank of America Earnings Top Views

    Benzinga | Jan. 19, 2016 | 10:05AM EST
  3. Benzinga's Top #PreMarket Losers

    Benzinga | Dec. 9, 2015 | 08:28AM EST
  4. Benzinga's Volume Movers

    Benzinga | Dec. 1, 2015 | 10:25AM EST
  5. Morning Market Losers

    Benzinga | Nov. 30, 2015 | 09:51AM EST
  6. Benzinga's Top #PreMarket Losers

    Benzinga | Nov. 30, 2015 | 08:25AM EST
  7. Morning Market Losers

    Benzinga | Nov. 27, 2015 | 09:50AM EST
  8. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 27, 2015 | 08:08AM EST
  9. UPDATE: Aeterna Zentaris Affirms Business, Prospects Remain Fundamentally Strong

    Benzinga | Nov. 25, 2015 | 13:02PM EST
  10. Benzinga's Volume Movers

    Benzinga | Nov. 24, 2015 | 11:06AM EST
  11. Morning Market Gainers

    Benzinga | Nov. 24, 2015 | 09:56AM EST
  12. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 24, 2015 | 08:15AM EST
  13. Aeterna Zentaris Offers Details of Steps to Regain NASDAQ Compliance

    Benzinga | Nov. 18, 2015 | 08:35AM EST
  14. Aeterna Zentaris Announces Amendment to Series B Warrants, Enters Definitive Agreement With ~90% Of Outstanding Series B Holders

    Benzinga | Sep. 21, 2015 | 09:04AM EST
  15. Aeterna Zentaris Reports Data, Safety Monitoring Board Scheduled to Close Second Interim Analysis of ZoptEC Phase 3 Trial in Early October

    Benzinga | Aug. 11, 2015 | 07:33AM EST
  16. Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen in AGHD

    Benzinga | Jun. 25, 2015 | 07:31AM EST
  17. Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research

    Benzinga | Dec. 29, 2014 | 07:31AM EST
  18. Aeterna Zentaris Adds Hollings Cancer Center To Multi-National Phase 3 Trial In Endometrial Cancer

    Benzinga | Nov. 20, 2014 | 07:32AM EST
  19. Morning Market Losers

    Benzinga | Nov. 6, 2014 | 09:56AM EST
  20. UPDATE: H.C. Wainwright Initiates Coverage On AEterna Zentaris

    Benzinga | Jul. 17, 2014 | 08:51AM EST
  21. Morning Market Losers

    Benzinga | Jan. 9, 2014 | 10:10AM EST
  22. Aeterna Zentaris Announces Proposed Unit Offering; Pricing, Number of Units to be Determined

    Benzinga | Jan. 8, 2014 | 16:14PM EST
  23. Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by FDA

    Benzinga | Jan. 6, 2014 | 12:03PM EST
  24. Aeterna Zentaris Names Dr. Richard Sachse as Chief Scientific Officer

    Benzinga | Jan. 3, 2014 | 07:39AM EST
  25. Stocks Hitting 52-Week Lows

    Benzinga | Nov. 20, 2013 | 10:15AM EST
  26. Morning Market Losers

    Benzinga | Nov. 20, 2013 | 09:58AM EST
  27. Aeterna Zentaris Prices 13.1M Unit Offering at $1.15/Unit

    Benzinga | Nov. 20, 2013 | 08:29AM EST
  28. Billionaires Hold Waning Biotechs 42% Off

    GuruFocus | Oct. 13, 2013 | 17:18PM EST
  29. Aeterna Zentaris Closes Transfer of Cetrotide Rights to Merck

    Benzinga | Oct. 1, 2013 | 07:33AM EST
  30. UPDATE: Canaccord Genuity Reiterates Hold Rating, Raises PT on AEterna Zentaris

    Benzinga | Dec. 31, 2012 | 01:35AM EST
  31. Mid-Day Market Movers

    Benzinga | Dec. 28, 2012 | 04:48AM EST
  32. Benzinga's Top Pre-Market Gainers

    Benzinga | Dec. 28, 2012 | 01:14AM EST
  33. Aeterna Zentaris Granted SPA by FDA for Phase 3 AEZS-108 Registration Trial in Endometrial Cancer

    Benzinga | Dec. 28, 2012 | 00:36AM EST
  34. Benzinga's Top Pre-Market Gainers

    Benzinga | Dec. 11, 2012 | 01:17AM EST
  35. Aeterna Zentaris Announces Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting

    Benzinga | Nov. 26, 2012 | 00:35AM EST
  36. Aeterna Zentaris Presents Promising Results for Disorazol Z Cytotoxic Conjugates

    Benzinga | Nov. 8, 2012 | 01:25AM EST
  37. Stocks Hitting 52-Week Lows

    Benzinga | Oct. 22, 2012 | 04:12AM EST
  38. Aeterna Zentaris Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule

    Benzinga | Oct. 22, 2012 | 01:37AM EST
  39. Aeterna Zentaris Announces Pricing of US $16.5 Million Public Offering of Common Shares and Warrants

    Benzinga | Oct. 12, 2012 | 02:57AM EST
  40. Benzinga's Top Pre-Market Losers

    Benzinga | Oct. 12, 2012 | 02:22AM EST
  41. Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants

    Benzinga | Oct. 11, 2012 | 10:14AM EST
  42. Benzinga's Microcap Movers for Thursday September 20, 2012

    Benzinga | Sep. 20, 2012 | 13:56PM EST
  43. Benzinga's Microcap Movers for Monday August 14, 2012

    Benzinga | Aug. 14, 2012 | 11:47AM EST
  44. Aeterna Zentaris Granted Patent in the U.S. for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency

    Benzinga | Aug. 7, 2012 | 01:33AM EST
  45. Six Flags Entertainment, Sanmina-SCI Corporation Among Stocks Gapping Up Tuesday

    FoxBusiness | Jul. 24, 2012 | 04:31AM EST
  46. Aeterna Zentaris Requests Fast Track Designation from the FDA for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency

    Benzinga | Jul. 24, 2012 | 02:41AM EST
  47. Benzinga's Microcap Movers for Tuesday June 26, 2012

    Benzinga | Jun. 26, 2012 | 11:09AM EST
  48. Aeterna Zentaris Announces Final Phase 3 Results for AEZS-130 in Adult Growth Hormone Deficiency Presented at ENDO Meeting

    Benzinga | Jun. 26, 2012 | 01:31AM EST
  49. Aeterna Zentaris: Phase 1 Results Show Perifosine's Activity Against Neuroblastoma

    Benzinga | Jun. 21, 2012 | 01:31AM EST
  50. Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price

    Benzinga | May. 16, 2012 | 10:16AM EST
Trading Center